Table 2.
Rates and risks of primary and secondary outcomes in the follow-up period with s-IPTW adjustment.
| Dabigatran | Rivaroxaban | Warfarin | |
|---|---|---|---|
| Fatal or non-fatal major bleeding events | |||
| Number of patients | 6682 | 20,422 | 12,231 |
| Number of events | 130 | 614 | 455 |
| Number of person-years | 5010 | 14,940 | 8770 |
| Incidence rate per 1000 person-years (95 % CI) | 26 (22.00–31.00) | 41 (38.00–44.00) | 52 (47.00–57.00) |
| Incidence proportion, n (%) |
130 (1.95 %) | 614 (3.01 %) | 455 (3.72 %) |
| Composite outcome of stroke, SE, MI, all-cause mortality (inpatient), major bleeding, major GI bleeding (hospitalization due to GI bleeding), or ICH | |||
|---|---|---|---|
| Number of patients | 6682 | 20,422 | 12,231 |
| Number of events | 922 | 2963 | 2055 |
| Number of person-years | 4323 | 12,986 | 7461 |
| Incidence rate per 1000 person-years (95 % CI) | 213 (200.00–228.00) | 228 (220.00–237.00) | 275 (264.00–288.00) |
| Incidence proportion, n (%) |
922 (13.8 %) | 2963 (14.51 %) | 2055 (16.8 %) |
Abbreviations: CI = confidence interval; GI = gastrointestinal; ICH = intracranial hemorrhage; MI = myocardial infarction; SE = systemic embolism; s-IPTW = stabilized inverse probability of treatment weighting.